Cure8 research brief
Genetic variation in MYO9B has been linked to Crohn’s disease, ulcerative colitis, and celiac disease. This study suggests a plausible epithelial-cell mechanism — altered microvilli and RhoA signaling — that could help explain how MYO9B variants influence disease risk or intestinal barrier function.
Researchers studying IBD genetics, epithelial biology, and barrier function; translational scientists exploring non-immune mechanisms of IBD; clinicians interested in the biological basis of IBD-associated genetic variants.
This is a basic-science preprint reporting lab experiments in mouse ileum and human cell models. The authors used live-cell super-resolution microscopy and a RhoA activity biosensor to show that Myo9b moves to microvillus tips and regulates local RhoA signaling, affecting microvillus abundance and dynamics.
Knockout of Myo9b altered microvillus number and dynamics but did not completely remove microvilli or apical localization of Ezrin, a key microvillus regulator.
By contrast, cells engineered to carry the Myo9b-S1011A disease variant as the only copy lost microvilli and Ezrin apical localization, pointing to a possible disruptive effect of that variant on epithelial structure.
These findings point to a mechanistic link between MYO9B variation and epithelial morphology, but they do not demonstrate clinical effects in people or therapeutic implications.
This is a preprint (basic-science) and has not completed peer review. Findings are from cell and mouse models and do not establish that the S1011A variant causes disease in people or that modifying Myo9b would be therapeutic. The study focuses on cellular mechanism (microvilli architecture and RhoA signaling), not clinical outcomes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
The paper links a Crohn’s disease GWAS signal to reduced LACC1 expression in lymphocytes and to altered immunometabolic function, clarifying a potential mechanism by which genetic variation contributes to IBD risk. It...
